



16 September 2024

Vineet Agarwal appointed to dorsaVi Board

Melbourne, Australia, 16 September 2024: dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**) is pleased to announce the appointment of Mr Vineet Agarwal to dorsaVi's Board of Directors as Non-Executive Director effective 16 September 2024.

Mr Agarwal is a seasoned professional with significant commercial expertise spanning over 18 years in the technology sector. Mr Agarwal is currently Product Management Director at Advanced Micro Devices (NASDAQ:AMD), where he has overseen the successful management and product launch of the Ryzen Client Product line. At AMD, Mr Agarwal was instrumental in the development of the Ryzen AI, which integrates advanced AI capabilities directly into central processing units. Prior to AMD, Mr. Agarwal held strategic roles at Qualcomm (NASDAQ:QCOM), including Director of Program Management and Senior Manager, driving the development of QCOM's Snapdragon platform.

Mr Agarwal's appointment aligns with dorsaVi's strategic objective to innovate and expand its AI technological capabilities. His familiarity with cutting-edge innovations such as Ryzen AI and Qualcomm's AI-powered Snapdragon systems positions him uniquely to provide valuable insights and strategic direction to dorsaVi. Mr Agarwal's product management and hardware design expertise supports dorsaVi's integration of emerging technology to its sensors, reducing future development costs, and accelerating time-to-market for new products. Mr Agarwal holds a MBA from The Wharton School of the University of Pennsylvania and Masters degrees in electrical and computer engineering from the University of Arizona.

Mr Vineet Agarwal commented:

"I am honoured to join dorsaVi's Board and contribute to the company's impressive journey. dorsaVi's focus on AI-enabled sensor technology and its commitment to innovation align perfectly with my background in products and engineering. I look forward to helping drive dorsaVi's growth strategy and expanding its capabilities in the digital healthcare sector."

Mr Michael Panaccio, dorsaVi's Chairman commented:

"We are thrilled to welcome Vineet to dorsaVi's Board of Directors. His extensive experience in the AI and technology sectors make him an invaluable addition to our team as we continue to pursue our strategic goal of enhancing our AI-focused product offering. We are excited to leverage Vineet's insights and connections to explore new growth opportunities, enhance our technology, and deliver greater value to our shareholders."

The release of this announcement was authorised by the Board of dorsaVi.

– ENDS –

For further information about dorsaVi, please contact:

dorsaVi

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
ar@dorsavi.com

Investors

Joel Seah
Vesparum Capital
+61 3 8582 4800
dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com

For personal use only